UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Industries, Ltd.,

Plaintiffs,

V.

Civil Action No. 14-CV-2758 (PAC)

Amneal Pharmaceuticals, LLC,

Defendants.

Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Industries, Ltd.,

Plaintiffs,

V.

Civil Action No. 14-CV-2760 (PAC)

Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (dba Zydus Cadila),

Defendants.

Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Industries, Ltd.,

Plaintiffs,

V.

Civil Action No. 14-CV-2759 (PAC)

Orient Pharma Co., Ltd.,

Defendants.



Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Industries, Ltd.,

Plaintiffs,

V.

Sawai USA, Inc., and Sawai Pharmaceutical Co., Ltd.,

Defendants.

Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Industries, Ltd.,

Plaintiffs,

V.

Apotex, Inc. and Apotex Corp.,

Defendants.

Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Industries, Ltd.,

Plaintiffs,

V.

Lupin Ltd. and Lupin Pharmaceuticals, Inc.,

Defendants.

Civil Action No. 14-CV-5575 (PAC)

Civil Action No. 14-CV-7934 (PAC)

Civil Action No. 15-CV-3935 (PAC)



DEFENDANTS PROPOSED FINDINGS AND CONCLUSIONS OF LAW RE:

INVALIDITY OF THE '336 PATENT IN LIGHT OF THE DOCTRINE OF OBVIOUSNESS-TYPE DOUBLE PATENTING

PRESENTED ON BEHALF OF AMNEAL, ORIENT, SAWAI AND ZYDUS



TABLE OF CONTENTS

I.	PROPOSED FINDINGS OF FACT REGARDING THE INVALIDITY OF THE '33' PATENT UNDER THE DOCTRINE OF OBVIOUSNESS-TYPE DOUBLE							
	PATE	NTING	j	1				
	A.	Technical Background						
		1.	Stereochemistry of a molecule – generally.	1				
		2.	Statins	2				
		3.	Salts	3				
	B.	The '336 Patent						
		1.	Background	5				
		2.	The Definition of a Person of Ordinary Skill in the Art	7				
	C.	The Obviousness-Type Double Patenting References						
		1.	Patent No. 5,872,130	8				
		2.	Patent No. 5,284,953 ("the '953 Patent")	10				
II.	CLAI	PROPOSED CONCLUSIONS OF LAW REGARDING THE INVALIDITY OF CLAIMS 1 AND 2 OF THE '336 PATENT UNDER THE DOCTRINE OF						
	OBVI	OUSNI	ESS-TYPE DOUBLE PATENTING OBVIOUSNESS	15				
	A.	Obvio	ousness-Type Double Patenting-Legal Standard	16				
	B.	Claims 1 and 2 of the '336 Patent Are Invalid for Obviousness Type Double-Patenting In View of Claims 1 and 5 of the '130 Patent						
		1.	The '130 Patent and the '336 Patent Have the Same Assignee and Inventors	18				
		2.	Plaintiffs Have not Rebutted that Claims 1 and 2 of the '336 Patent is Patentably Indistinct from Claims 1 and 5 of the '130 Patent	18				
		3.	The '130 Patent Is Available as an Obviousness-Type Double Patenting Reference					
			a) The Safe Harbour Provision of 35 U.S.C. §121 is Inapplicable	21				
		4.	The '130 Patent Is Available as an Obviousness Type Double Patenting Reference	22				



Case 1:14-cv-02758-PAC Document 106 Filed 12/16/16 Page 5 of 40

C.	Claims 1 and 2 of the '336 Patent Are Invalid for Obviousness Type Double Patenting In View of Claim 1 of the '953 Patent					
	1.	The '	336 Patent and the '953 Patent Have the Same Assignee	23		
	2.	The (One-Way Test Applies	23		
	3.	The '336 Patent Is Patentably Indistinct from the '953 Patent Under the One-Way Test				
	4.		Claims 1 and 2 of the '336 Patent Is Patentably Indistinct from the Claim 1 of the '953 Patent Under the Two-Way Test			
		a)	It Would Have Been Obvious to Isolate the Single Steroisomer from the Mixture of Steroisomers			
		b)	It Would Have Been Obvious to Go from the Calcium Salt to the Phenethylamine Salt	he 34		



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

